Donamem
Formulated to alleviate progressive cognitive decline to support memory retention and target daily behavioural coordination.
Donamem details
- Conditions
- Alzheimer's Disease · Dementia
- Alternative names
- donepezil, memantine
- Therapeutic class
- Cholinesterase Inhibitor, NMDA Receptor Antagonist Combination
- Pharmacological class
- Alzheimer's Disease Therapy
- Contraindications
- severe hepatic impairment; hypersensitivity to any component
- Minor side effects
- diarrhoea; nausea; dizziness
- Moderate side effects
- headache; insomnia; confusion
- Serious side effects
- severe bradycardia, requires immediate medical attention
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Sun Pharma
- Onset Time
- 2–4 weeks
- Duration
- 24 hours
- Storage instructions
- Store below 25°C.
- Drug interactions
- Amantadine; NSAIDs; Ketoconazole
- Age restrictions
- Approved for adults.
Patient summary
formulated to alleviate progressive cognitive decline to support memory retention and target daily behavioural coordination.
Mechanism of action
Combines donepezil to increase synaptic acetylcholine with memantine to regulate glutamate activity and prevent excitotoxic injury.
Pregnancy and breastfeeding
TGA Category C: Use if potential benefit outweighs risk. Breastfeeding: Consult a doctor.